CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Kurt Von Emster sold 144,216 shares of the stock in a transaction on Friday, January 19th. The stock was sold at an average price of $10.25, for a total transaction of $1,478,214.00. Following the transaction, the director now directly owns 90,000 shares in the company, valued at $922,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Kurt Von Emster also recently made the following trade(s):

  • On Friday, January 5th, Kurt Von Emster sold 4,300 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $10.21, for a total transaction of $43,903.00.
  • On Friday, December 22nd, Kurt Von Emster sold 173,192 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.41, for a total transaction of $1,629,736.72.
  • On Friday, November 10th, Kurt Von Emster sold 50,048 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.26, for a total transaction of $463,444.48.
  • On Tuesday, October 31st, Kurt Von Emster sold 59,209 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.27, for a total transaction of $548,867.43.

CymaBay Therapeutics Inc (CBAY) traded up $0.25 during trading on Monday, hitting $10.45. 667,015 shares of the company’s stock were exchanged, compared to its average volume of 564,037. CymaBay Therapeutics Inc has a 12-month low of $1.46 and a 12-month high of $10.60. The company has a market capitalization of $458.38, a price-to-earnings ratio of -10.35 and a beta of 1.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.39 and a quick ratio of 7.39.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). During the same quarter in the previous year, the company earned ($0.25) EPS. sell-side analysts forecast that CymaBay Therapeutics Inc will post -0.82 earnings per share for the current fiscal year.

Several research analysts recently issued reports on CBAY shares. Cantor Fitzgerald reissued a “buy” rating and set a $16.00 target price on shares of CymaBay Therapeutics in a research note on Wednesday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $12.00 price objective on shares of CymaBay Therapeutics in a research note on Friday, October 27th. Zacks Investment Research lowered shares of CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. Finally, Oppenheimer set a $15.00 price objective on shares of CymaBay Therapeutics and gave the company a “buy” rating in a research note on Monday, October 30th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $14.50.

Several institutional investors have recently added to or reduced their stakes in CBAY. Boothbay Fund Management LLC purchased a new stake in shares of CymaBay Therapeutics in the third quarter valued at about $404,000. Perceptive Advisors LLC purchased a new stake in shares of CymaBay Therapeutics in the third quarter valued at about $18,948,000. Ardsley Advisory Partners raised its holdings in shares of CymaBay Therapeutics by 66.2% in the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock valued at $290,000 after purchasing an additional 20,000 shares during the last quarter. EAM Investors LLC purchased a new stake in shares of CymaBay Therapeutics in the third quarter valued at about $4,788,000. Finally, Vanguard Group Inc. raised its holdings in shares of CymaBay Therapeutics by 20.7% in the second quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock valued at $5,712,000 after purchasing an additional 170,126 shares during the last quarter. 69.12% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Insider Selling: CymaBay Therapeutics Inc (CBAY) Director Sells 144,216 Shares of Stock” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2018/01/22/insider-selling-cymabay-therapeutics-inc-cbay-director-sells-144216-shares-of-stock.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.